BioCentury
ARTICLE | Clinical News

Cinryze regulatory update

December 20, 2016 12:50 AM UTC

EMA’s CHMP recommended expanding the label of Cinryze from Shire for treatment and pre-procedure prevention of angioedema attacks to include children ages 2-11 with hereditary angioedema (HAE); and fo...

BCIQ Company Profiles

Shire plc

BCIQ Target Profiles

Complement 1 (C1) esterase